Background -Allergic pruritus and urticaria in the horse are challenging for veterinarians and owners; little is known about their long-term management.
Introduction
The management of pruritus and urticaria due to allergic skin disease in the horse is challenging for veterinary surgeons and owners, and little is known about the long-term treatment requirements and progression of the disease over time.
In the horse, atopic dermatitis (AD), as a hypersensitivity reaction to environmental allergens and food, presents with pruritus or urticaria or both. [1] [2] [3] [4] [5] [6] [7] [8] It is typically described as a lifelong condition requiring ongoing treatment interventions; signs may be seasonal or perennial, depending on the causal allergens. 9 Allergens commonly implicated in many reports include house dust and storage mites, insects, pollens and epithelia. 6 As for other veterinary species, the diagnosis of equine AD is a clinical diagnosis based on compatible history, clinical signs and exclusion of other differential diagnoses such as ectoparasite infestations, Culicoides hypersensitivity and other insect bite hypersensitivities (IBH), and if possible adverse food reactions. Management strategies include allergen avoidance, topical therapies 10, 11 and systemic medications such as antihistamines, glucocorticoids and tricyclic antidepressants. 9 Dust and moulds can be found in high concentrations in various feeds and bedding materials 10, 12 , and implementation of allergen reduction measures has been shown to be beneficial in some horses with recurrent airway disease 13, 14 and in 18 of 19 horses with nonsummer seasonal and perennial pruritus with or without urticaria. 15 Management strategies may also include allergen-specific immunotherapy (ASIT) based on the results of allergen-specific IgE detected by intradermal testing (IDT) and serological methods. 3, 7, [16] [17] [18] [19] [20] [21] Positive IDT reactions may occur in normal horses, whereas atopic horses show more numerous and stronger positive reactions. 3, 22 Studies have reported variable efficacy of ASIT in equine AD, with up to 84% of cases showing good to excellent response to ASIT based on the results of intradermal testing. 1, 4, 8, [23] [24] [25] In one study, in horses where glucocorticoids could be stopped, 59% were well controlled with ASIT as the sole treatment and 9% of the partial responders needed doxepin in addition to ASIT. In 44% of cases, ASIT was stopped due to resolution of clinical signs, with two thirds of these reporting no recurrence of disease, but recurrence of clinical signs occurred within 1-12 years of stopping ASIT in the remaining one third. 8 The aims of this study were to investigate the progression of AD in horses after IDT and to summarize their IDT results. Owners' perceptions and reports on their horses' skin disease, on medical treatment utilized, including ASIT, and the effects of management changes over time were investigated through telephone questionnaires.
Methods and materials
The study had been approved by the Royal Veterinary College (RVC) Ethics and Welfare committee (R349).
Study population
Horses with suspected AD which had been referred for intradermal testing to one of two dermatology referral centres in southeastern England between 2006 and 2011 were enrolled. Horses had been diagnosed initially with allergic skin disease by their referring veterinary surgeon. At referral, allergic dermatitis was confirmed clinically based on a history and presenting signs of pruritus and/or urticaria after ectoparasite infestations and microbial infections had been ruled out. Dermatological examination was performed combined with microscopic examination of skin scrapings, coat brushings and/or with anti-ectoparasite therapy, cytological examination of lesions, and fungal or bacterial culture or antimicrobial therapy when indicated. Insect bite hypersensitivities were ruled out by confirming nonsummer seasonal or perennial disease from the medical records. Food hypersensitivity was discussed with every owner, and elimination diet trials were recommended; IDT was performed irrespectively, based on suspected AD.
Information on signalment (age, sex, breed or type), cutaneous signs relevant for referral for IDT (pruritus, urticaria, both, seasonality), previous therapy including response (glucocorticoids, antihistamines) and elimination diet trials was collected from electronic or paper medical histories as far as available.
Intradermal testing
All horses were tested using procedures as described previously 6 against allergens considered relevant including environmental mites and epithelia including feathers and pollens (grasses, weeds and flowers, trees). In addition, allergen solutions of insects, fungi, grain crop pollens, house dust, grain mill dust and smut were included when available. Allergen test kits varied minimally in their composition over the six year duration of the study due to differing availability of allergen solutions and preferences of referral centres. Allergens used were recorded for each horse from the medical records. Allergen solutions had been sourced over time from one of two manufacturers (Greer Laboratories; Lenoir, NC, USA, or ArtuVet; Lelystad, Netherlands) with concentrations and dilutions given in Table S1 .
Reactions were considered positive if the diameter of the wheal was greater than the mean of the positive and negative controls measured at 30 min. Wheal sizes were assessed at 30 min and 2-4 h (considered immediate and late-phase IgE-mediated reactions). Additional observations were made at 12-24 h to assess for delayed reactions. ASIT was offered for all horses showing positive reactions to allergens presumed to be clinically relevant and suitable for inclusion (indoor allergens, epithelia, pollens) and not for horses only showing reactions to moulds, fungi and insects.
Management changes were recommended for all horses, depending on groups of allergens implicated by IDT (indoor allergens and dusts, epithelia, pollens, insects) to reduce exposure (Table S2) . At Veterinary Dermatology Referrals (VDR), specific changes recommended included use of rubber matting in stables with minimal or no loose bedding, feeding of vacuum-packed, wilted grass products to replace hay and feeding of pelleted concentrate foods stored for only short periods in original packaging, regular, frequent rug laundering and quarterly pressure cleaning of stables, removal of bird nests and use of selective weed killer, if relevant.
Owner recruitment
Owners were telephoned between September 2013 and March 2014 and asked for their participation in a telephone questionnaire study on their horse's skin disease, medication, effect of ASIT and implementation of management changes since IDT. Owners were called from known telephone numbers (number not withheld by the caller) by the same investigator (DH) up to three times if there was no reply and no answering machine and up to two messages were left on answering machines before the case was excluded due to failed contact. Owners were not contacted if a horse was known to be dead since the IDT. For horses reported deceased by their owner during the telephone contact, the cause of death was recorded, but they were not asked to complete the questionnaire.
Questionnaires
Questions were divided into three broad topics. First, owners were asked to assess their horse's skin problem at the time of the telephone questionnaire and at the time of IDT. They were asked to describe skin signs as pruritic, urticarial, both or other, whether changes in type or distribution of problems had been observed since IDT and whether other skin problems had been diagnosed by their veterinarian since IDT. Owners were asked to assess the severity of itching and/or urticaria and provide a score between 0 and 10 (an unvalidated empirical score system; with 0 for normal/never and 10 for severe/present all the time).
Secondly, questions on medication and other treatments, specifically glucocorticoids, antihistamines, ASIT, antidepressants, nutritional supplements and washes, were asked. Sub-questions for each treatment were whether the horse had ever received it, was currently receiving it and how frequently (seasonally, throughout the year), whether the treatment was tolerated and whether the owner thought the treatment had improved skin problems.
Thirdly, owners were asked about their horses' current management and on implementation of management changes recommended at time of IDT (Table S2 ), including whether they had changed barn or paddock, where the horse spent most of its time, type of bedding used, rugging (type, time spent wearing rugs and frequency of laundering), clipping (frequency and extent) and ectoparasite and fly control measures. For each question, owners were asked whether they considered those changes beneficial to their horse's skin problem.
An option to answer 'unsure' or 'unknown' was included where appropriate. The questionnaire was trialled in six pilot calls and adjusted based on feedback. Each questionnaire was estimated to take 20 min including a short introduction outlining the study purpose, confidentiality provisions and the option to decline. At the end of the questionnaires, owners were offered contact details of investigators.
Data analysis
Microsoft Excel (Microsoft, v15.38, 2017) was used for data collection and SPSS version 23.0 (IBM; Armonk, NY, USA) for analysis.
Results
Enrolled horses and owners Eighty two horses had undergone IDT for suspected AD during the study period, 15 from the RVC, and 67 from VDR (original starting population). Ages at time of IDT ranged between one and 25 years (mean 9.9 years). There were 40 mares, 40 geldings, one stallion and one horse of unknown sex. Breeds or types varied, with 23 recorded as cob or pony, mostly Welsh cob, 21 as thoroughbred including thoroughbred crosses, seven Irish sports horses, eight warmbloods and 23 other types. Pruritus was the presenting complaint in 36 horses (43.9%), urticaria in 34 horses (41.5%) and 12 (14.6%) presented with both. In most horses (67 of 82, 81.7%), lesions were reported as generalized. Of the 15 horses with localized lesions, eight showed signs only on the trunk, six on the head and one on the legs. All animals suffered from skin disease during the winter months, for 19 horses (23.2%), owners reported additional seasonal flares during spring or summer.
Owners of 61 (74.4%) horses were contacted by telephone. For the remainder, either contact details were not available or attempts to make contact as described above had failed. One owner declined participation, and two could not provide answers because the horses had been sold soon after IDT. The time between IDT and telephone questionnaire for the 58 horses ranged between 28 and 88 months (mean 71 months or 5.9 years).
At the time of telephone contact, eleven of the 58 (19.0%) horses were reported dead, including four (6.9%) euthanized due to uncontrollable skin disease (three with pruritus, one with urticaria). One had died a spontaneous death of unconfirmed cause, five had been euthanized for known diagnoses [brain tumour, lymphoma, colic, lameness (investigated and confirmed as nonlaminitic), kissing spines] and one horse for old-age related reasons.
Intradermal tests
The average number of allergens each horse was tested against was 54.2 [standard deviation (SD) 10], and the average number of positive reactions per horse was 13 (SD 8.1). Two horses had shown no positive wheal and flare reactions to any of the allergens despite strong histamine test reaction. The allergens tested in at least 50 horses and which resulted in positive reactions in at least 25% of horses are listed in Table 1 . Most (1,247; 96.1%) of the 1,297 positive reactions recorded in total occurred at the early readings considered compatible with immediate and late-phase hypersensitivity reactions. At the later time points, compatible with delayed reactions, 122 (9.4%) positive reactions were recorded -72 at sites of earlier readings, 50 (3.9%) distributed over all allergen groups -that had not been recorded at earlier time points.
Skin disease -owner assessment Of the 47 horses for which follow-up information was available (14 RVC, 33 VDR), owners considered their horse's skin disease at the time of telephone contact as resolved without medication in 18 cases (38.3%), as improved with treatment in 25 cases (53.2%) and as unchanged or worse despite medication in four cases (8.5%). Six of the 18 horses that no longer had skin problems at the time of telephone contact had been lesion-free since the time of IDT whereas another ten had not had skin disease for at least the previous 2 years. Four of these 18 horses had had management changes implemented after IDT (see below), and two further horses only showed skin disease after known triggers (cereal-based food or treats, shavings). The remaining 29 horses were still receiving either glucocorticoids or antihistamines throughout the year or at least three times a year during flares. Six owners reported that their horses had been diagnosed with pituitary pars intermedia dysfunction since IDT and that new, different skin lesions had developed (crusting papules, urticaria in previously pruritic horses and vice versa).
Owners' assessment of pruritus, irrespective of medication or management used, on a 1-10 scale gave a median of 9 (range 3-10) at the time of IDT and of 1.5 (range 0-6) at the time of telephone contact. Median scores for the frequency of urticaria flares were 8 (range 2-10) at the time of IDT and 2 (range 0-7) at telephone contact.
Medication and immunotherapy -owner assessment Systemic glucocorticoids had been used in 35 of 47 horses (74.5%) to control skin disease since IDT, including seven still receiving treatment at the time of telephone contact. Good response to glucocorticoid therapy was reported in 94.3% of horses (33 of 35) after IDT, whereas good response had been recorded in 78.2% of the 55 horses that had been treated with glucocorticoids prior to IDT (plus a further 5.5% showing partial response). Adverse effects of post-IDT glucocorticoid therapy were reported by owners in seven of 35 (20%) including laminitis in one heavy draft horse (which according to the medical records was recorded as a foot abscess and without further mention of laminitis in the medical records during the subsequent two years), two horses with flares of pre-existing laminitis, and one each with drowsiness, weight gain or behaviour changes.
Twelve owners reported using topical glucocorticoid preparations (hydrocortisone aceponate spray (Cortavance, Virbac; Bury St Edmunds, UK) n = 6; fusidic acid/ betamethasone combination (Fuciderm, now Isaderm, Dechra Veterinary Products; Shrewsbury, UK) n = 4; unknown human eczema cream n = 1) and all but one owner observed a beneficial effect when the product was applied at least daily.
Twenty eight horses (59.6%) had received antihistamines (type unknown) at some stage since IDT to control their cutaneous signs, and good response was reported in 17 of these 28 horses (60.7%). Eight horses were still maintained on antihistamines as the sole medication at the time of telephone contact. Drowsiness was the only adverse effect reported in three horses.
ASIT had been ordered for 27 horses (57.5%), but its use was reported only by owners of 14 of 47 horses (29.8%) with nine owners of these 14 horses (64.3%) reporting a beneficial effect including eight reporting a 75-100% improvement. In only three horses was immunotherapy continued beyond the first prescribed immunotherapy vial of at least nine months; in one of them, antihistamines were given concurrently throughout. A further two horses were restarted on ASIT when clinical signs relapsed after immunotherapy had been discontinued following completion of injections with the initial vial. Restarting ASIT was perceived as helpful again in both cases. The remaining nine horses no longer received ASIT at the time of telephone contact. Six owners stated they thought they had finished the treatment after the initial vial (typically nine months), including three in which treatment was thought to have had no effect. Another two owners stopped ASIT before completing the initial vial due to lack of effect, and one owner stated expense as the reason for stopping. Twelve owners reported administering the maintenance injections themselves (injections by the veterinarian as default administration type). No systemic adverse effects were reported, localized injection site reactions were seen by owners in six of 14 horses (42.9%) on individual occasions, none persisted or required veterinary attention.
Fly prevention was used in 22 (46.8%) horses regularly during the spring and summer. In total, 38 horses (82.1%) were receiving or had received other agents with the aim to control their skin disease since IDT. These included systemic antimicrobial therapy (n = 1), shampoo therapy used at least weekly (n = 18) with seven owners using chlorhexidine-based products and 11 using products of unknown composition but with claims of alleviating allergic skin signs [and 12 of 38 owners (31.6%) perceiving a beneficial effect]. Skin-related, nonprescription food supplements (various, unknown) had been given by 30 owners (65.2%) without adverse effects reported.
Management changes
Twenty two owners (46.8%) had implemented recommended changes to stables, bedding, feed or rugs, and nine of those (40.9%) reported a perceived subsequent improvement in their horse's skin disease, including four horses for which no additional medication had been needed since. Skin disease was reported to have improved in three horses after they had been relocated to a different yard, in another three following dietary changes (treats removed from diet), one horse improved when shavings were removed from its stable, and in the remaining two horses, multiple changes had been made concurrently.
Almost all horses (45; 97.8%) were reported to wear rugs at some time during the year with 34 wearing the rug all day during the cooler months. Thirty five of 47 (74.5%) horses were regularly clipped.
Discussion
To the best of the authors' knowledge, this is the first study in the UK to report on the management of atopic horses over time, with a reporting interval greater than two years available for all cases. Although information derived from owner interviews was collected retrospectively and is inevitably associated with a high degree of subjectivity, it still provides a realistic insight into the burden of allergic skin disease on horses and their owners and may help to stimulate future research and improvements in clinical management. In addition, questionnaire data were collected during the colder months of the year in the UK which may have biased reporting. However, in the UK, clinical signs and onset of AD in the horse have been reported throughout the year 2 and including onset and exacerbation in autumn, suggesting that the impact of seasonality may be less relevant.
The data on clinical signs and IDT results collected from medical records were broadly in line with previous studies, 8, 16 including one in southern England. 6 Positive reactions to house dust mites, storage mites and insects predominated, likely reflecting exposure to such allergens through a largely stabled lifestyle and management, including the frequent use of house dust mite-harbouring rugs, 26 with exposure to biting insects when at pasture. Results from this study on disease outcome at least two years after IDT were highly surprising, first with regard to the substantial proportion of horses for which owners reported that skin disease had resolved and treatment had not been required for at least two years, and secondly, with regard to the number of deceased horses.
These findings challenge the concept that AD in the horse is chronic and requires lifelong treatment. 5, 7, 9 Unfortunately, our data do not allow conclusions to be made on duration of disease before resolution in these horses, and so predictions cannot be made on how long signs might persist in horses with potentially transient presentations. However, the results suggest that, at least in some horses, the prognosis for AD can be excellent and they further corroborate previous advice that it is best to explore possible causes when the disease is recurrent or persistent. 27 Whether resolution of skin signs without medication was spontaneous or due to management changes, which were perceived to help by almost half of the owners, remains unknown. The role of allergen load rather than exposure is less clear for AD compared to respiratory lower airway disease in the horse. 28 However, in the absence of such data, the benign nature of recommendations on management changes warrants inclusion in the management plan for every atopic horse presented for IDT.
In contrast, the finding that 19% of horses were dead at the time of telephone interview, including 7% (four horses) where owners reported that the animals had been euthanized due to uncontrollable skin disease, is concerning. Although research on the pathomechanisms and treatment options on allergic diseases has progressed substantially over the past decades, the social implications of chronic allergic diseases are only slowly starting to receive attention. Initial results of a survey on health-related quality of life in atopic dogs and on quality of life in their owners showed that the disease had a deeply negative impact on both measures but only 1% of owners stated they had contemplated euthanasia. 29 In addition, treatment was considered a major financial burden by a third of dog owners and 40% stated that they had to limit other expenses as a consequence. The questionnaire in our study was not designed to further explore reasons for euthanasia, but the results are likely to reflect some degree of welfare concerns, implications on the use of a horse with skin disease and the financial burden associated with chronic skin disease. Other horse-specific factors also may have played a role and need to be investigated further.
Of the 29 horses for which management of skin disease was still required after IDT, different combinations of antihistamines, glucocorticoids, ASIT and management changes were reported to achieve acceptable levels of control with tolerable adverse effects for most patients and owners. Results on drug efficacy need to be interpreted with care as these were based on owner impressions over time rather than on veterinary assessment following a defined intervention period. However, the high frequencies of beneficial effects reported for glucocorticoids (94.3%), mainly as oral prednisolone, and for antihistamines (60.7%) provide some assurance on treatment effect. To date, despite their wide use, only review articles describe the use of both medications in the treatment of allergic skin disease in horses and provide some pharmacokinetic information and dose recommendations. 9, 23 Further study is needed on which therapies or combinations help atopic horses most, and if there is a difference in response to therapies between pruritic and urticarial horses which was not the focus of this study. Slightly more information is available on the use of glucocorticoids for noninfectious lower airway disease where inflammation is thought to contribute to clinical signs. 28 Concerns over glucocorticoid use as a risk factor in the development of laminitis are widespread, but the scientific basis for this association is sparse, at least for nonpredisposed horses. [30] [31] [32] Results from two studies suggested that such a link may have been overestimated, 33, 34 but due to the critical consequences of laminitis, further research is still needed. In light of the relatively high number of atopic horses in this study, which were euthanized due to uncontrolled disease, with none due to laminitis caused by glucocorticoid therapy, concerns over the potential risk of laminitis need to be balanced against welfare considerations due to uncontrolled AD. In the authors' opinion, glucocorticoids have an important role to play in the management of atopic horses; prednisolone at low doses given on alternate days to horses not predisposed to laminitis would be a recommended strategy. 9 The benefit of ASIT reported in 64% of horses in this study was lower than the 84% owner-reported efficacy from a North American study of 41 horses receiving ASIT, 8 but comparable to those found in a previous study. 25 However, the low uptake of ASIT following IDT in this study was surprising and disappointing. Reasons for not starting or at least not pursuing therapy were not explored as these findings had been unexpected. Measures have been taken since the conclusion of the study to extend discussion with owners and strengthen recommendations towards ASIT.
Although "much folklore still remains in respect of certain equine skin diseases" as stated in 1970 by the late LR Thomsett, 35 the results from the present study on long-term management of allergic horses from the owners' perspective indicate that AD may have a better prognosis than in other companion animals and may not always be chronic. It is still of concern, though, that there was a high number of euthanized horses in this study, suggesting that severe cases may be difficult to control and that the burden of chronic skin disease for owners should not be underestimated. Management changes, following the identification of relevant allergens by IDT, in combination with medication and sometimes ASIT, may help provide effective control of clinical signs.
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Additional Supporting Information may be found in the online version of this article. Table S1 . Allergen solutions and dilutions used for intradermal testing of horses during the study period. Table S2 . Suggestions on management changes provided to horse owners to reduce exposure to environmental mites in atopic horses Resumen Introducci on -el prurito al ergico y la urticaria en caballos son complicados para los veterinarios y los propietarios; poco se sabe sobre su control a largo plazo. Objetivos -presentar los resultados de las pruebas intrad ermicas frente a alergenos (IDT) y evaluar la percepci on de los propietarios acerca de la enfermedad de la piel, y los efectos del tratamiento m edico y los cambios en el manejo de sus caballos at opicos a lo largo del tiempo. Animales -Ochenta y dos caballos con dermatitis at opica en el sureste de Inglaterra entre 2006 y 2011. M etodos y materiales -los resultados de IDT se revisaron de forma retrospectiva. Los propietarios completaron cuestionarios telef onicos sobre cambios en la piel, medicamentos, efecto de la inmunoterapia espec ıfica de al ergenos (ASIT) y administraci on. Resultados -Sesenta y un dueños (74,4%) pudieron ser contactados con un promedio de 5,9 años (rango 28-88 meses) despu es de IDT; de ellos, tres no pudieron ser inscritos. De los 58 caballos restantes, once (19%) hab ıan fallecido en el momento de la entrevista con el propietario, incluidos cuatro (6,9%) sacrificados debido a una enfermedad cut anea incontrolable. Los 47 propietarios restantes informaron que los signos de la enfermedad de la piel no se hab ıan visto durante al menos dos años en 18 caballos (38,3%), incluidos dos que solo presentaban enfermedad con alergenos conocidos. Veintinueve caballos (61,7%) a un necesitaban medicamentos para controlar la enfermedad de la piel, aunque 25 (53,2%) requirieron menos desde la prueba. Los propietarios informaron de un efecto beneficioso de ASIT en nueve de 14 caballos (64,3%); de glucocorticoides en 33 de 35 (94,3%) y de antihistam ınicos en 17 de 28 (60,7%). Se implementaron cambios de manejo espec ıficos para 22 caballos y se reportaron como beneficiosos en nueve de 22 (40,9%). Conclusiones -la dermatitis at opica equina puede no ser siempre cr onica, pero los casos graves parecen dif ıciles de controlar. IDT puede ayudar a formular ASIT y puede ayudar a guiar los cambios en el manejo. 
